To date, there has not been a clinical trial of a MELKi in melanoma; yet, there is an ongoing phase-1 trial of MELKi in advanced breast cancer and triple-negative breast cancer (NCT02926690), suggesting the prognostic and potentially therapeutic relevance of MELK in tumor progression. The gene discussed is MELK; the disease is melanoma.